The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts ...

As previously announced with regard to the EU, the clinical trial approval with EMA was granted under the condition that the Company present results of appropriate nonclinical GLP studies before ...

The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial ("EMERALD-1”), ...

It is the latest U.S. firm to make the move, which includes the London office, easing the switch with a two-week August WFH ...

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a ...